90K 预测胶质母细胞瘤患者的预后，并增强肿瘤裂解物脉冲树突状细胞疫苗用于 GBM 的免疫治疗。

90K predicts the prognosis of glioma patients and enhances tumor lysate-pulsed DC vaccine for immunotherapy of GBM .

机构信息

Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China.

National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China.

出版信息

Aging (Albany NY). 2021 Mar 3;13(6):8355-8368. doi: 10.18632/aging.202645.

OBJECTIVES

This study aimed to investigate the relationship between 90K expression with glioma malignancy and prognosis. Additionally, the enhancement effect of 90K in the Dendritic cell (DC) vaccine for Immunotherapy of glioblastoma (GBM) was evaluated .

METHODS

The expression of 90K protein in glioma tissues was detected by western blot. The relationship between the 90K expression and the tumor grade as well as the prognosis of patients was further analyzed by mining TCGA and CGGA database. The concentration of IL-12p70 and IL-10 was detected by ELISA. T lymphocyte proliferation and lethal effect of cytotoxic T cell (CTL) were detected by CCK-8.

RESULTS

The expression of 90K was significantly higher in glioma than normal tissue and increased with tumor grade (P< 0.05). Higher 90K expression was observed in IDH wildtype glioma than IDH mutant and predicted worse overall survival for glioma patients. The concentration of IL-12p70 and IFN-γ was the highest in the Apoptosis U251-90K-DC group, in which group the ability to kill U251 cells by CTL was also the strongest.

CONCLUSION

90K was a useful biomarker for glioma malignancy and patient prognosis. The appearance of 90K enhanced the effect of Apoptosis U251-DC vaccine for immunotherapy of GBM.

目的

本研究旨在探讨 90K 表达与胶质瘤恶性程度和预后的关系。此外，还评估了 90K 对树突状细胞（DC）疫苗免疫治疗胶质母细胞瘤（GBM）的增强作用。

方法

通过 Western blot 检测胶质瘤组织中 90K 蛋白的表达。通过挖掘 TCGA 和 CGGA 数据库，进一步分析 90K 表达与肿瘤分级以及患者预后的关系。通过 ELISA 检测 IL-12p70 和 IL-10 的浓度。通过 CCK-8 检测 T 淋巴细胞增殖和细胞毒性 T 淋巴细胞（CTL）的致死效应。